Industry News

• Intrexon and Surterra Wellness partner in $100 million deal for cannabinoids fermentation  Intrexon and Surterra Wellness announced an exclusive global licensing agreement. The companies advance Surterra's cannabinoid production at a reliable, efficient, cost-effective, industrial scale utilizing Intrexon's proprietary yeast fermentation platform.
  June 18, 2019  
• Arcadia Biosciences announces closing of $7.5 million registered direct offering   Arcadia announced the closing of its registered direct offering of 1,489,575 shares of its common stock. The offering was priced at $4.91 per share for gross proceeds of $7.31 million. Arcadia also issued unregistered warrants to purchase up to 1,489,575 shares of common stock.
  June 18, 2019  
• ContraVir Pharmaceuticals announces pricing of $15.6 million public offering  ContraVir Pharma announced pricing of a public offering with expected gross proceeds of $15.6 million. Roth Capital Partners is acting as the lead placement agent for the offering. Arcadia Securities is acting as co-placement agent for the offering.
  June 18, 2019  
• Rockwell Medical announces pricing of $17.5 million public offering of common stock  Rockwell Medical announced pricing of its underwritten public offering of 5,833,334 shares of its common stock at a public offering price of $3.00 per share. Rockwell Medical granted the underwriters a 30-day option to purchase up to an additional 875,000 shares of its common stock.
  June 18, 2019  
• Rocket Pharma announces dosing has commenced in phase 1 clinical trial of RP-A501  Rocket Pharmaceuticals announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector-based gene therapy for treatment of Danon disease. UCSD Health is the initial and lead center for the Phase 1 clinical trial.
  June 18, 2019  
• Lannett launches aspirin and extended-release dipyridamole capsules  Lannett announced it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox® Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals.
  June 18, 2019  
• FDA approves KEYTRUDA (pembrolizumab) as monotherapy for metastatic SLCc  Merck announced the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
  June 18, 2019  
• Calithera Bio announces commencement of underwritten public offering of common stock  Calithera Biosciences announced it intends to offer and sell 10,000,000 shares of its common stock in an underwritten public offering. Calithera expects to grant the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock.
  June 17, 2019  
• Illumina wins infringement suit against Ariosa Diagnostics  Illumina announced the High Court of Justice, Chancery Division, Patents Court in the UK issued a judgment in its favor in the patent infringement suit filed against Ariosa Diagnostics. The Court found that Ariosa’s Harmony non-invasive prenatal test infringed EP 1 524 321.
  June 17, 2019  
• Rockwell Medical announces proposed public offering of common stock  Rockwell Medical announced it has commenced an underwritten public offering of its common stock. Rockwell Medical intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price.
  June 17, 2019  

   (next 10 articles)